NCT07047001View on ClinicalTrials.gov

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2032

Conditions
Renal Cell Carcinoma (RCC)Adjuvant
Interventions
DRUG

Vorolanib Tablets

200mg PO QD

DRUG

Vorolanib + Toripalimab

"Vorolanib: 100mg PO QD~Toripalimab: 240mg IV infusion Q3W"

Trial Locations (1)

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Dong Wen

OTHER